Institut Jules Bordet, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.
Future Oncol. 2013 Aug;9(8):1105-19. doi: 10.2217/fon.13.57.
Breast cancer oncology represents one of the disciplines where personalized cancer medicine has been most actively pursued. The class-discovery studies conceptually advanced the field, underlining the molecular heterogeneity governing this common disease. The advent of high-throughput molecular profiling technologies holds great promise for the advance of all aspects of personalized cancer medicine, namely accurate prognostication, prediction of response to common systemic therapies and individualized monitoring of the disease. Moreover, an ever-expanding arsenal of targeted therapeutic compounds under clinical development, coupled with emerging powerful tools for comprehensive molecular and functional characterization, pose significant promise for improved clinical outcomes for breast cancer patients. Interrogation of the germline genetic variation offers further promise towards tailoring of breast cancer management. Well-conducted prospective validation studies are needed if breast cancer personalized therapy is to transform from a dream into a reality.
乳腺癌肿瘤学是个性化癌症医学最活跃的领域之一。分类发现研究概念上推动了该领域的发展，强调了控制这种常见疾病的分子异质性。高通量分子谱分析技术的出现为个性化癌症医学的各个方面带来了巨大的希望，即准确预测预后、预测对常见全身治疗的反应以及对疾病的个体化监测。此外，临床开发中不断扩展的靶向治疗化合物库，加上用于全面分子和功能特征分析的新兴强大工具，为改善乳腺癌患者的临床结果带来了重大希望。对种系遗传变异的研究进一步为乳腺癌的管理提供了个性化的方案。如果要将乳腺癌的个体化治疗从梦想变为现实，就需要进行精心设计的前瞻性验证研究。
